| GSDMD |
Oxidation |
Cys192 (only tested in mouse) |
Promotes oligomerization and pore formation |
119
|
| GSDMD |
Oxidation |
Cys38, Cys56, Cys268, Cys467 (only tested in human) |
Promotes cleavage by caspase-1 |
116
|
| GSDMD |
Disulfiram |
Cys191/Cys192 (human/mouse) |
Inhibits pore formation |
127
|
| GSDMD |
Necrosulfamide |
Cys191/Cys192 (human/mouse) |
Inhibits pore formation |
128
|
| GSDMD |
Succination (fumarate/DMF) |
Cys191/Cys192 (human/mouse) |
Inhibits cleavage by caspase-1 and pore formation |
126
|
| GSDMD |
Itaconation |
Cys77 (mouse-specific; not present in human) |
Most likely inhibitory |
124
|
| GSDMD |
Phosphorylation |
Thr213 (only tested in human) |
Inhibits pore formation |
130
|
| GSDMD |
Lys27-linked polyubiquitination |
Lys203, Lys204/Lys204, Lys205 (human/mouse) |
Promotes pyroptosis |
132
|
| GSDMD |
Lys63-linked/ Lys48-linked polyubiquitination |
LysK55, Lys62, Lys203 (human-specific) |
Targeting for degradation |
55,56,133,135
|
| GSDMD |
Palmitoylation |
Cys192 |
Promotes membrane association |
120,121
|
| GSDMA |
Phosphorylation |
Thr8 (only tested in human) |
Inhibits pore formation |
105
|
| GSDMB |
Lys48-linked polyubiquitination |
At least Lys177, Lys190, Lys192 (only tested in human) |
Targeting for degradation and direct inhibition of pore formation |
55,56,133–135
|
| GSDME |
Phosphorylation |
Thr6 (only tested in human) |
Inhibits pore formation |
105
|
| GSDME |
Disulfiram |
Undefined |
Inhibits pore formation |
129
|
| GSDME |
Succination (fumarate/DMF) |
Cys45 |
Inhibits pyroptosis |
126
|
| GSDME |
Palmitoylation |
Cys407/Cys408 (human/mouse) |
Promotes pyroptosis |
123
|
| Bacterial GSDMs |
Palmitoylation |
Cys3/Cys3/Cys4/Cys7 (Runella/Bradyrhizobium/ Vitiosangium/Lysobacter) |
Promotes membrane permeabilization |
122
|
